Delivery Order SPE2DB22D9304-SPE2DB25FSSW9
Award Date
6/24/25
Potential Completion Date
7/16/25
Potential Value
$10K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA) under the Medical Supply Chain program. The firm fixed-price delivery order, valued at $7,146.90, has an ultimate completion date of September 19, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications, including branded and generic...
This federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS. The firm fixed-price contract has a ceiling value of $8,331.72 and a period of performance through July 7, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the supply of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA). The $7,146.90 firm fixed-price delivery order has an ultimate completion date of September 17, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The award has a ceiling value of $8,576.28 and is a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications and medical supplies to support the recurring medical needs...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The $3,471.55 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has an ultimate completion date of July 1, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $8,331.72 firm-fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS, with a completion date of June 26, 2025. DMS Pharmaceutical Group is an established federal contractor, holding a significant Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999 through November 2026. This IDC enables the DLA to issue delivery...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Nexplanon 68 mg implants. The contract, valued at $6,943.10, has an ultimate completion date of May 12, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue delivery orders...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business (WOSB) pharmaceutical wholesaler, provides NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA). The $7,146.90 firm fixed-price delivery order contract has an ultimate completion date of August 21, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $8,576.28 for the supply of NEXPLANON 68 MG IMPLANTS. The award was made by the Defense Logistics Agency (DLA) under the SPE2DB program, which is an indefinite delivery contract (IDC) with a ceiling value of up to $499,999,999 that runs through December 31, 2025. DMS Pharmaceutical Group holds this single-award IDC to provide a comprehensive range of...
The Defense Logistics Agency awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NEXPLANON 68 MG IMPLANTS. The $3,573.45 contract has a completion date of February 13, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that holds various federal contracts and indefinite delivery vehicles to supply pharmaceuticals and medical products in support of military treatment facilities worldwide. This delivery order is...